{
    "address1": "1 North Waukegan Road",
    "city": "North Chicago",
    "state": "IL",
    "zip": "60064-6400",
    "country": "United States",
    "phone": "847 932 7900",
    "website": "https://www.abbvie.com",
    "industry": "Drug Manufacturers\u2014General",
    "industryDisp": "Drug Manufacturers\u2014General",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.",
    "fullTimeEmployees": 50000,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Mr. Richard A. Gonzalez",
            "age": 68,
            "title": "Chairman & CEO",
            "yearBorn": 1954,
            "fiscalYear": 2022,
            "totalPay": 6948244,
            "exercisedValue": 0,
            "unexercisedValue": 43528872
        },
        {
            "maxAge": 1,
            "name": "Mr. Robert A. Michael",
            "age": 52,
            "title": "Pres & COO",
            "yearBorn": 1970,
            "fiscalYear": 2022,
            "totalPay": 3998042,
            "exercisedValue": 0,
            "unexercisedValue": 13150419
        },
        {
            "maxAge": 1,
            "name": "Mr. Scott T. Reents",
            "age": 54,
            "title": "Exec. VP & CFO",
            "yearBorn": 1968,
            "fiscalYear": 2022,
            "totalPay": 2972736,
            "exercisedValue": 0,
            "unexercisedValue": 5172329
        },
        {
            "maxAge": 1,
            "name": "Dr. Azita  Saleki-Gerhardt Ph.D.",
            "age": 59,
            "title": "Exec. VP & COO",
            "yearBorn": 1963,
            "fiscalYear": 2022,
            "totalPay": 2576755,
            "exercisedValue": 0,
            "unexercisedValue": 28534760
        },
        {
            "maxAge": 1,
            "name": "Mr. Jeffrey Ryan Stewart",
            "age": 53,
            "title": "Exec. VP & Chief Commercial Officer",
            "yearBorn": 1969,
            "fiscalYear": 2022,
            "totalPay": 2983231,
            "exercisedValue": 2777988,
            "unexercisedValue": 10864175
        },
        {
            "maxAge": 1,
            "name": "Dr. Thomas J. Hudson M.D.",
            "age": 60,
            "title": "Sr. VP of R&D and Chief Scientific Officer",
            "yearBorn": 1962,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Elizabeth  Shea",
            "title": "VP of Investor Relations",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Tracie  Haas",
            "title": "Sr. VP of Corp. Responsibility, Brand & Communications",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Timothy J. Richmond",
            "age": 56,
            "title": "Exec. VP & Chief HR Officer",
            "yearBorn": 1966,
            "fiscalYear": 2013,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Nicholas R. Donoghoe M.D.",
            "age": 41,
            "title": "Exec. VP and Chief Bus. & Strategy Officer",
            "yearBorn": 1981,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 9,
    "boardRisk": 7,
    "compensationRisk": 7,
    "shareHolderRightsRisk": 9,
    "overallRisk": 9,
    "governanceEpochDate": 1693526400,
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 148.91,
    "open": 149.0,
    "dayLow": 148.2,
    "dayHigh": 149.76,
    "regularMarketPreviousClose": 148.91,
    "regularMarketOpen": 149.0,
    "regularMarketDayLow": 148.2,
    "regularMarketDayHigh": 149.76,
    "dividendRate": 5.92,
    "dividendYield": 0.0397,
    "exDividendDate": 1697068800,
    "payoutRatio": 1.1893001,
    "fiveYearAvgDividendYield": 4.49,
    "beta": 0.547026,
    "trailingPE": 30.662552,
    "forwardPE": 13.47378,
    "volume": 4339818,
    "regularMarketVolume": 4339818,
    "averageVolume": 5257330,
    "averageVolume10days": 3915330,
    "averageDailyVolume10Day": 3915330,
    "bid": 0.0,
    "ask": 0.0,
    "bidSize": 1800,
    "askSize": 1300,
    "marketCap": 263027752960,
    "fiftyTwoWeekLow": 130.96,
    "fiftyTwoWeekHigh": 168.11,
    "priceToSalesTrailing12Months": 4.694996,
    "fiftyDayAverage": 144.6214,
    "twoHundredDayAverage": 150.36716,
    "trailingAnnualDividendRate": 5.85,
    "trailingAnnualDividendYield": 0.039285474,
    "currency": "USD",
    "enterpriseValue": 315686256640,
    "profitMargins": 0.15502,
    "floatShares": 1762275557,
    "sharesOutstanding": 1765049984,
    "sharesShort": 13259308,
    "sharesShortPriorMonth": 9506806,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.0075,
    "heldPercentInsiders": 0.00131,
    "heldPercentInstitutions": 0.71415,
    "shortRatio": 2.53,
    "shortPercentOfFloat": 0.0075,
    "impliedSharesOutstanding": 1765049984,
    "bookValue": 7.29,
    "priceToBook": 20.441702,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "earningsQuarterlyGrowth": 1.19,
    "netIncomeToCommon": 8634999808,
    "trailingEps": 4.86,
    "forwardEps": 11.06,
    "pegRatio": -3.26,
    "enterpriseToRevenue": 5.635,
    "enterpriseToEbitda": 10.813,
    "52WeekChange": 0.047665954,
    "SandP52WeekChange": 0.08443928,
    "lastDividendValue": 1.48,
    "lastDividendDate": 1689206400,
    "exchange": "NYQ",
    "quoteType": "EQUITY",
    "symbol": "ABBV",
    "underlyingSymbol": "ABBV",
    "shortName": "AbbVie Inc.",
    "longName": "AbbVie Inc.",
    "firstTradeDateEpochUtc": 1357137000,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "73238d42-cdcc-3f92-8141-dd675addae10",
    "messageBoardId": "finmb_141885706",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 149.02,
    "targetHighPrice": 205.0,
    "targetLowPrice": 135.0,
    "targetMeanPrice": 169.14,
    "targetMedianPrice": 167.0,
    "recommendationMean": 2.4,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 25,
    "totalCash": 8766000128,
    "totalCashPerShare": 4.966,
    "ebitda": 29195999232,
    "totalDebt": 61392998400,
    "quickRatio": 0.628,
    "currentRatio": 0.895,
    "totalRevenue": 56022999040,
    "debtToEquity": 475.988,
    "revenuePerShare": 31.651,
    "returnOnAssets": 0.09175,
    "returnOnEquity": 0.63017,
    "grossProfits": 41527000000,
    "freeCashflow": 23683999744,
    "operatingCashflow": 25542000640,
    "earningsGrowth": 1.234,
    "revenueGrowth": -0.049,
    "grossMargins": 0.70473,
    "ebitdaMargins": 0.52114,
    "operatingMargins": 0.36498,
    "financialCurrency": "USD",
    "trailingPegRatio": 5.9143,
    "parent_etfs": [
        "AGNG"
    ]
}